Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules

Details for Australian Patent Application No. 2006289290 (hide)

Owner Immatics Biotechnologies GmbH

Inventors Dengjel, Jorn

Agent Pizzeys

Pub. Number AU-B-2006289290

PCT Pub. Number WO2007/028574

Priority 05019254.1 05.09.05 EP

Filing date 5 September 2006

Wipo publication date 15 March 2007

Acceptance publication date 25 November 2010

International Classifications

C07K 14/47 (2006.01) Peptides having more than 20 amino acids

A61K 39/00 (2006.01) Medicinal preparations containing antigens or antibodies

Event Publications

20 March 2008 PCT application entered the National Phase

  PCT publication WO2007/028574 Priority application(s): WO2007/028574

25 November 2010 Application Accepted

  Published as AU-B-2006289290

24 March 2011 Standard Patent Sealed

8 December 2011 Alteration of Name

  The name of the patentee has been altered to immatics biotechnologies GmbH

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006289304-Insertion instrument for an endoprosthesis comprising a prosthesis shaft which is to be inserted into a marked chamber

2006289289-Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine